Intrexon Corporation (XON) Forecasted to Post Q1 2018 Earnings of ($0.21) Per Share
Intrexon Corporation (NYSE:XON) – Analysts at Griffin Securities issued their Q1 2018 EPS estimates for Intrexon Corporation in a research report issued to clients and investors on Monday. Griffin Securities analyst K. Markey anticipates that the biotechnology company will post earnings of ($0.21) per share for the quarter. Griffin Securities also issued estimates for Intrexon Corporation’s Q2 2018 earnings at ($0.19) EPS, Q3 2018 earnings at ($0.18) EPS and Q4 2018 earnings at ($0.17) EPS.
Intrexon Corporation (NYSE:XON) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.05. The business had revenue of $54.40 million during the quarter, compared to analysts’ expectations of $57.17 million. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.42) EPS.
XON has been the subject of several other reports. Zacks Investment Research lowered Intrexon Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. BidaskClub upgraded Intrexon Corporation from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 15th. Finally, Northland Securities set a $30.00 price objective on Intrexon Corporation and gave the stock a “buy” rating in a research note on Monday, August 7th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Intrexon Corporation has an average rating of “Hold” and a consensus target price of $40.50.
Intrexon Corporation (XON) traded down 0.48% during trading on Wednesday, reaching $18.54. The company’s stock had a trading volume of 241,382 shares. Intrexon Corporation has a one year low of $17.70 and a one year high of $32.90. The stock has a 50-day moving average of $22.53 and a 200 day moving average of $21.91. The firm’s market capitalization is $2.23 billion.
Several large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its stake in Intrexon Corporation by 2,031.7% in the second quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock worth $125,000 after buying an additional 4,937 shares during the period. Pacer Advisors Inc. raised its stake in Intrexon Corporation by 21.6% in the first quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock worth $146,000 after buying an additional 1,305 shares during the period. SG Americas Securities LLC bought a new stake in Intrexon Corporation during the first quarter worth about $164,000. Federated Investors Inc. PA bought a new stake in Intrexon Corporation during the second quarter worth about $172,000. Finally, Cullinan Associates Inc. bought a new stake in Intrexon Corporation during the second quarter worth about $201,000. Institutional investors and hedge funds own 84.52% of the company’s stock.
In related news, CEO Randal J. Kirk purchased 132,625 shares of the company’s stock in a transaction dated Friday, August 11th. The stock was acquired at an average cost of $18.85 per share, for a total transaction of $2,499,981.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Dean J. Mitchell purchased 5,000 shares of the company’s stock in a transaction dated Friday, August 11th. The stock was bought at an average price of $18.33 per share, with a total value of $91,650.00. Following the completion of the transaction, the director now directly owns 18,103 shares of the company’s stock, valued at $331,827.99. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 141,719 shares of company stock valued at $2,669,554. 56.30% of the stock is owned by company insiders.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.